CUSIP: 30315R107
Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
9,120,825
-
Share change
-
+1,154,418
-
Total reported value
-
$57,641,580
-
Put/Call ratio
-
2689%
-
Price per share
-
$6.32
-
Number of holders
-
56
-
Value change
-
+$8,273,129
-
Number of buys
-
20
-
Number of sells
-
26
Quarterly Holders Quick Answers
What is CUSIP 30315R107?
CUSIP 30315R107 identifies FSTX - F-STAR THERAPEUTICS INC - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q1 2023
-
Previous quarter:
Q3 2022
Recent filing periods for CUSIP 30315R107:
Institutional Holders of F-STAR THERAPEUTICS INC - COM (FSTX) as of Q4 2022
As of 31 Dec 2022,
F-STAR THERAPEUTICS INC - COM (FSTX) was held by
56 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
9,120,825 shares.
The largest 10 holders included
ARMISTICE CAPITAL, LLC, Rock Springs Capital Management LP, Trium Capital LLP, Atlas Venture Life Science Advisors, LLC, DAFNA Capital Management LLC, Atlas Venture Advisors, Inc., Weiss Asset Management LP, Russell Investments Group, Ltd., Crystalline Management Inc., and BlackRock Inc..
This page lists
56
institutional shareholders reporting positions in this security
for the Q4 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.